Table 1.
Safety and Efficacy Clinical Trials for EVs in COVID-19 disease
| Clinical Phase | Intervention | Status | Trial Identifier | Route of administration | Outcome |
|---|---|---|---|---|---|
| II |
Bone marrow MSCs-EVs (ExoFlo™) |
Not recruiting |
(EXIT COVID-19) |
Intravenous | -- |
| Access |
Bone marrow MSCs-EVs (ExoFlo™) |
Active | NCT04657458 | Intravenous | -- |
| -- |
Cardiosphere-EVs (CAP-1002) |
Inactive | NCT04338347 | Intravenous | -- |
| I | T cell exosomes | Not |
(CSTC-Exo) |
Aerosol | -- |
| I & II | Amniotic fluid EVs (Zofin™) | recruiting | NCT04384445 | Intravenous | -- |
| I | Adipose MCSs | Recruiting | NCT04276987 | Aerosol | -- |
| I & II | MSCs (EXO1 and EXO2) | Complete |
(COVID-19EXO) |
Aerosol | -- |